NCT01072175 - Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 | Biotech Hunter

Enrollment

430

Participants

Timeline

Start Date

March 26, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

February 27, 2018

Conditions

Cancer

Interventions

DRUG

GSK2118436

GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.

DRUG

GSK1120212

GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.

Trial Locations (15)

2145

Novartis Investigative Site, Westmead

3084

Novartis Investigative Site, Heidelberg

19104

Novartis Investigative Site, Philadelphia

21093

Novartis Investigative Site, Lutherville-Timonium

33612

Novartis Investigative Site, Tampa

37203

Novartis Investigative Site, Nashville

37232

Novartis Investigative Site, Nashville

55905

Novartis Investigative Site, Rochester

80045

Novartis Investigative Site, Aurora

90025

Novartis Investigative Site, Los Angeles

94115

Novartis Investigative Site, San Francisco

06520

Novartis Investigative Site, New Haven

02114

Novartis Investigative Site, Boston

02215

Novartis Investigative Site, Boston

77030-4009

Novartis Investigative Site, Houston